United Therapeutics director sells 200 shares

UNITED THERAPEUTICS Corp director Judy D. Olian sold common stock in a planned transaction.

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp director Judy D. Olian sold common stock in a planned transaction. On March 6, 2026, she completed an open-market sale of 200 shares of common stock at a price of $510 per share, leaving her with 4,645 shares held directly.

According to a footnote, this sale was made under a pre-arranged Rule 10b5-1 trading plan that she entered into on November 24, 2025. Such plans are designed to allow insiders to systematically sell shares over time according to predetermined instructions.

Insights

Insider trading and governance analyst

Small, pre-planned director share sale under 10b5-1 plan.

Director Judy D. Olian sold 200 shares of UNITED THERAPEUTICS Corp common stock on March 6, 2026 at $510 per share, described as an open-market sale. Following this transaction, she directly holds 4,645 shares.

A footnote explains the sale occurred pursuant to a pre-arranged Rule 10b5-1 plan entered into on November 24, 2025. These plans are commonly used to schedule trades in advance, helping separate personal trading decisions from day-to-day corporate information. On its own, this modest, pre-planned sale appears routine rather than thesis-changing.

Insider Trade Summary

Net Seller: 200 shares

Net Sell 1 txn

Insider Olian Judy D.

Role Director

Sold 200 shs ($102K)

Type	Security	Shares	Price	Value
Sale	Common Stock	200	$510.00	$102K

Holdings After Transaction: Common Stock — 4,645 shares (Direct)

Footnotes (1)

1. F1. This is a sale of common stock pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 24, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did UNITED THERAPEUTICS (UTHR) director Judy D. Olian report on this Form 4?

She reported selling 200 shares of UNITED THERAPEUTICS Corp common stock. The transaction was an open-market sale at $510 per share, leaving her with 4,645 shares held directly after the trade, according to the Form 4 disclosure.

When did Judy D. Olian sell UNITED THERAPEUTICS (UTHR) shares and at what price?

She sold the shares on March 6, 2026, at $510 per share. The Form 4 describes this as an open-market sale of 200 shares of UNITED THERAPEUTICS Corp common stock, with direct ownership remaining at 4,645 shares afterward.

How many UNITED THERAPEUTICS (UTHR) shares does Judy D. Olian own after this transaction?

After the reported sale, she directly owns 4,645 shares of UNITED THERAPEUTICS Corp common stock. This figure is explicitly listed in the Form 4 as the total number of shares beneficially owned following the March 6, 2026 transaction.

Was the UNITED THERAPEUTICS (UTHR) share sale by Judy D. Olian under a 10b5-1 plan?

Yes. A footnote states the sale was made under a pre-arranged Rule 10b5-1 trading plan. That plan was entered into by Judy D. Olian on November 24, 2025, providing a pre-set schedule for selling shares independent of day-to-day corporate developments.

What type of transaction did the UNITED THERAPEUTICS (UTHR) Form 4 disclose?

The Form 4 discloses a non-derivative open-market sale of common stock. It records a transaction code “S,” identifying a sale of 200 shares of UNITED THERAPEUTICS Corp common stock at $510 per share by director Judy D. Olian.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 04:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Olian Judy D.

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		S(1)		200	D	$510	4,645	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This is a sale of common stock pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 24, 2025.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.